Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Huge Success of Monoclonal Antibodies
- Technology in a Nutshell
- Major Monoclonal Technology Leaders
- Spectrum Expert Commentary: Monoclonal Antibodies as Drug Delivery Agents
- Red Hot Monoclonal Products and Markets
- Rituximab-Targeted B-Cell Therapy
- Trastuzumab-Targeted HER2 Therapy
- Bevacizumab-First Approved Antiangiogenesis Therapy
- Cetuximab-First MAb to Treat Colorectal Cancer
- Sales Growth and Market Share of Cancer-Targeting MAbs
- A Run on MAb Companies
- Amgen Acquires Abgenix
- Panitumumab
- Denosumab
- Combination Treatments
- Manufacturing Facility
- Antibody Patent Rights
- AstraZeneca to Acquire Cambridge Antibody Technology
- Merck & Co. Acquires Abmaxis
- Deal Strategies
- Making the Switch from Platform-Based to Product-Based Company
- Overflowing Clinical Pipelines for MAbs
- When Things Go Very Wrong
- Pricing and Reimbursement Controversies
- Bevacizumab
- Cetuximab and Trastuzumab
- Cost-Containment Measures
- Companion Diagnostics
- Outlook
Tables
- 1. Key Technology Leaders-Evolution of MAb Technologies
- 2. Financial Position of Key MAb Technology Leaders, 2005
- 3. Ranking of MAbs by Indication and Worldwide Sales
- 4. Select Codevelopment Alliances for MAbs in Cancer, 2004-2006
- 5. Late-Stage MAbs in Clinical Development for Cancer
- 6. Sales of Currently Marketed Cancer MAbs
Figures
- 1. Worldwide Sales of Select MAbs, 2005
- 2. MAbs: From Mouse to Human
- 3. Sales of MAbs by Therapeutic Indication, 2002 and 2005
- 4. Market Cap of Key MAb Companies .
|
Related Report
|
View Cart
